Cytoki Pharma develops targeted therapeutics utilizing biopharmaceutical techniques to create precision medicines that treat diseases at the molecular level. The company focuses on unmet medical needs by improving patient outcomes and minimizing treatment side effects through tailored drug formulations.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metabolic diseases like obesity and type 2 diabetes, as well as conditions characterized by epithelial injury such as inflammatory bowel disease (IBD), present significant unmet medical needs. Current treatments often fail to achieve lasting disease modification and may be associated with undesirable side effects.
Solution
Cytoki Pharma is developing a new class of medicines based on the biology of IL-22 to address metabolic diseases and conditions involving epithelial injury. Their lead drug candidate, CK-0045, is a long-acting IL-22 analogue currently in Phase 2 clinical evaluation. CK-0045 aims to drive lasting disease modification through healthy weight loss and broader metabolic effects, offering a potential new treatment paradigm for cardiometabolic diseases.
Target Audience
The primary target audience includes individuals living with cardiometabolic diseases, such as obesity and type 2 diabetes, as well as those with conditions characterized by epithelial injury like inflammatory bowel disease.
Features
- CK-0045: A long-acting analogue of the naturally occurring cytokine IL-22.
- Designed to target metabolic diseases, including obesity and type 2 diabetes.
- Potential application in conditions characterized by epithelial injury, such as inflammatory bowel disease (IBD).
- Currently in Phase 2 clinical evaluation.
- Aims to achieve lasting disease modification through healthy weight loss.
- Seeks to provide broader, independent metabolic effects beyond weight loss.